Short Squeeze Potential On ALEC Gets Hotter

At the start of this week we talked about the short squeeze potential on Alector, Inc. (ALEC). That potential has just gotten bigger as the stock has steadily risen from $35 during a shaky week for the markets and is set to open above $40 on Friday. ALEC rose 57% last Friday after signing a $2.2 billion deal with GlaxoSmithKline (GSK) to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases. This deal includes a $700 million upfront payment, including $500 million coming in Q3, which is key to understanding the potential of the short squeeze. According to Yahoo Finance, ALEC has 6.7 million in short interest. This is 12% of the float, but consider that volume has tapered off quite a bit this week to an average of 2 million shares traded on Wednesday and Thursday. So it will get harder and harder to cover that short as volume goes down but price goes up. 


























What is going on here? Certain funds were shorting ALEC not because they hate the company, but because they thought ALEC will need to do a financing soon. They are vultures who short the stock then try to cover by looking for cheap financing deals. This is where the problem lies for them. With $700 million upfront payment coming, this should be sufficient for ALEC to cover all its cash needs in the foreseeable future. No cheap financing deal will come. Shorts tried to catch ALEC desperate for cash and take advantage of a vulnerable company. Now the tables have been completely reversed as shorts may be the ones in financial trouble, having taken a beating last Friday and potentially forced to cover at an even higher price.

There is a recent example similar to ALEC which is Intellia Therapeutics, Inc. (NTLA). Looking at its Yahoo Finance stats, you can see how similar it is to ALEC. Particularly with short interest and the short percentage of float. 

























On June 28, NTLA shot up 50% to $133.43 and shorts were screaming for a pullback, assuming a financing would happen at a low price. Instead the financing happened at $145 and the stock squeezed to over $200 two days later. Even with the pullback it's still in the $150's. This is the exact same thing we expect to happen on ALEC. Watch ALEC closely today and into next week.

Comments

Post a Comment

Popular posts from this blog

The Two Best Biotech Short Squeeze Candidates And The Next Carvana

Image
With the market having recovered most of its recent drop to be near all-time highs once again, shorts have been destroyed and are in a desperate spot. Heavily shorted stocks like B. Riley Financial, Inc. (RILY), Globe Life Inc. (GL) and Carvana Co. (CVNA) have been on absolute tears. We have written about CVNA before , as well as the impact of CVNA's move on Root , Inc. (ROOT). When a stock is squeezing like CVNA, a related stock like ROOT will follow suit. Shorts are often shorting multiple related stocks. Most don't even hide it with Kerrisdale openly bragging about its poor track record. GL was another one that was attacked by shorts which we talked about as a gamma squeeze candidate that has worked out very well over the past three weeks.  In this market of short squeezes, we have identified two excellent biotech short squeeze candidates, ImmunityBio, Inc. (IBRX) and Soleno Therapeutics, Inc. (SLNO). IBRX is starting up the production and sale of its cancer drug ANKT...
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by broker...
Read more

Forget about CVNA, PLCE is the Next Major Short Squeeze Play

Image
 Back in June, we called out Kerrisdale Capital and its short on Carvana Co. (CVNA) in our piece " Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale ". Kerrisdale has a history of calling one bad short after another, creating a squeeze on all of its positions as the firm and its associates face liquidity crises. Kerrisdale is once again on a cold streak as its short on Altimmune, Inc. (ALT) simultaneously blew up just as CVNA headed from $70 to $80 this week.  However, we think CVNA is done for now. Recall that in June after the initial spike to nearly $30, the stock pulled back to $20 before hitting $40 in the next month. People who are riding weekly call options aren't likely to cash in. CVNA looks headed to the mid to low $60's to close the gap that currently exists in the $62 to $66 area before resuming any further rise. Kerrisdale created an artificial short squeeze with its report, but now that both ALT and CVNA have come down from their weekly hig...
Read more